Warning: The NCBI web site requires JavaScript to function. more...
Adherence with urate-lowering therapies for the treatment of gout.
Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS.
Arthritis Res Ther. 2009;11(2):R46. Epub 2009 Mar 27.
Related citations
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
Thiele RG, Schlesinger N.
Rheumatol Int. 2010 Feb;30(4):495-503. Epub 2009 Jun 20.
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.
Ann Rheum Dis. 2009 Jan;68(1):51-6. Epub 2008 Feb 4.
Treatment of the gout and other forms of crystal-induced arthritis.
Rodnan GP.
Bull Rheum Dis. 1982;32(5):43-53. Review. No abstract available.
Crystal arthropathies: recognizing and treating "the gouch".
Quillen DM.
Prim Care. 2010 Dec;37(4):703-11, v. Review.
Uric acid lowering therapy: prescribing patterns in a large cohort of older adults.
Solomon DH, Avorn J, Levin R, Brookhart MA.
Ann Rheum Dis. 2008 May;67(5):609-13. Epub 2007 Aug 29.
Opportunities for improving medication use and monitoring in gout.
Singh JA, Hodges JS, Asch SM.
Ann Rheum Dis. 2009 Aug;68(8):1265-70. Epub 2008 Aug 13.
Adherence to urate-lowering therapy.
Day RO.
South Med J. 2009 Jan;102(1):114-5. No abstract available.
[Gout: diagnosis and therapy].
Schlapbach P.
Ther Umsch. 1985 Oct;42(10):687-90. Review. German. No abstract available.
Update on emerging urate-lowering therapies.
Chohan S, Becker MA.
Curr Opin Rheumatol. 2009 Mar;21(2):143-9. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):106.
Impact of allopurinol use on urate concentration and cardiovascular outcome.
Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM.
Br J Clin Pharmacol. 2011 Apr;71(4):600-7. doi: 10.1111/j.1365-2125.2010.03887.x.
[Hyperuricemia and gout: therapeutic indications].
Pawlotsky Y.
Rev Prat. 1994 Jan 15;44(2):206-9. French.
New treatments for gout.
Perez-Ruiz F.
Joint Bone Spine. 2007 Jul;74(4):313-5. Epub 2007 May 15. No abstract available.
Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP, Gilliland WR.
Clin Pharmacol Ther. 2011 Sep;90(3):363-4. doi: 10.1038/clpt.2011.146.
Risks and benefits of drugs used in the management and prevention of gout.
Conaghan PG, Day RO.
Drug Saf. 1994 Oct;11(4):252-8. Review.
Gout: joint pain and more.
[No authors listed]
Harv Mens Health Watch. 2007 Dec;12(5):1-3. No abstract available.
Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A.
Arthritis Rheum. 2002 Aug;47(4):356-60.
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C.
Arthritis Res Ther. 2010;12(2):R63. Epub 2010 Apr 6.
A short trial assessment of uricosuric therapy in gout.
Palmer DG, Highton TC.
Australas Ann Med. 1968 Aug;17(3):242-7. No abstract available.
Febuxostat--treatment for hyperuricemia and gout?
Moreland LW.
N Engl J Med. 2005 Dec 8;353(23):2505-7. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on